This animation created by Nature Reviews Cancer and Nature Reviews Immunology illustrates how tumour cells are sensed and destroyed by cells of the immune system and how tumours can evolve to evade immune-mediated elimination. Scientists are developing new immunotherapies that help the immune system to ‘fight back’ — the animation explains how these exciting new drugs work.
Nature has full responsibility for all editorial content, including Nature Video content. This content is editorially independent of sponsors.
Sign up for the Nature Briefing: An essential round-up of science news, opinion and analysis, free in your inbox every weekday. https://go.nature.com/371OcVF
Many genetic and environmental factors can cause tumors to form.
For instance, UV radiation from the sun can damage DNA
and other structures in melanocytes,
which are the pigment-producing cells in the skin.
Chronic damage to melanocytes by UV radiation
leads to most cases of melanoma, which is a type of skin cancer.
As melanomas grow, they can eventually spread to other sites in the body,
such as the lungs and liver.
The cells of the immune system are continuously monitoring our tissues.
Natural killer cells, or NK cells,
sense stress-associated molecules on damaged and cancerous cells.
Dendritic cells, or DCs, activate cytotoxic T cells,
which can then sense tumor-associated antigens
using their T cell receptor and other co-receptors.
Once activated, NK cells and cytotoxic T cells
release perforin and granzymes.
These molecules punch holes in the surface of the tumor cells,
causing them to die by apoptosis.
Helper T cells support these responses.
They help DCs to activate cytotoxic T cells,
and they produce cytokines, such as interferon gamma,
that recruit and activate more NK cells.
As the tumor evolves, genetic changes occur
that can give some tumor cells a survival advantage.
This means tumors are often heterogeneous.
For instance, tumor cells may no longer express the molecules
that are sensed by the killer immune cells.
As the immune system continues to kill the tumor cells it can recognize,
the cells it can't sense become more prevalent.
This is immunoediting.
It leads to the emergence of a tumor that can't be detected by the immune system.
Some tumor cells actively suppress T cells
by expressing inhibitory molecules, such as PD-L1.
PD-L1 binds to the PD-1 receptor on T cells and deactivates them.
This is an immune checkpoint.
In addition, tumor cells can attract immune cells
that suppress the activity of other immune cells,
thereby supporting tumor growth.
These immunosuppressive cells include regulatory T cells
and certain types of myeloid cells.
Therefore, the tumor microenvironment is like the scene of a battle
between two opposing immune responses.
One side of the immune system is attacking the tumor,
while the other side is helping it to grow.
Scientists are developing immunotherapies to help strengthen the immune attack.
One approach is adoptive T cell transfer.
Cytotoxic T cells taken from patients with melanoma
are selected for their ability to attack tumor cells.
The best killers are infused back into the patient.
Treating patients with cytokines, such as interleukin-2 and interferon-alpha,
can also boost the activity of anti-tumor immune cells.
An alternative approach is to target the immune checkpoints.
For instance, antibodies that bind to PD-1
stop this molecule from switching off cytotoxic T cells.
Another immune checkpoint being targeted is CTLA-4.
Blocking this molecule helps DCs to drive anti-tumor T cell responses.
Not all patients will respond to these immunotherapies
and some responses will be delayed.
Combining immunotherapies with chemotherapy or radiotherapy
can lead to a better response in some patients.
Immunotherapies can themselves be combined.
For example, PD-1 and CTLA-4 blockade
can improve responses when administered in combination.
Activating the immune system has risks.
Some patients develop harmful side effects
when their immune system attacks healthy cells.
Nevertheless, there have been encouraging results from clinical trials.
This animation has focused on melanoma,
but it's becoming clear that immunotherapies
can be used to treat many different types of cancer.